Company
gracellbio
Pioneering the Next Generation of CAR-T Cell Therapies
Also known as Gracell, Gracell Biotechnologies Inc.
- Status
- Acquiredas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2017
- Legal name
- Gracell Biotechnologies Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cell therapies.
Funding snapshot
- Total raised
- $390MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Secondary, $150M2023-08
Funding rounds
- Secondary
- $150M2023-08, Company stated
- IPO
- $240M2021-01, Company stated
- Series C
- 2020-10
- Series B
- 2019-02
About the company
- Status notes
- Gracell announced the completion of the acquisition by AstraZeneca
Exit
- Acquisition
- 2024-02-22
Loading relationship preview